Cidara Thera (CDTX) Stock Price, Quote & News

Company Profile

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enab...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 752 6170

Website: www.cidara.com

Address:

6310 Nancy Ridge Drive, Suite 101, San Diego, United States

AlphaOfBiotech Jan. 15 at 5:08 AM

$FATE is trading at half of its cash of $226M (as of late 2025). You are essentially getting the entire iPSC pipeline, 500+ patents, and a state-of-the-art manufacturing facility for free. What is happening to $CDTX $VTYX $TERN las last year will be repeated here soon! Wish us good luck! Go $FATE !

1 · Reply

Pjdevx Jan. 14 at 10:01 PM

$CADL If $CDTX is a 9B acquisition CADL is right up there. Willing to wait.

0 · Reply

Hero07 Jan. 13 at 7:15 PM

$NUVB Dr. Hung knows the Value in stacking ROA1 patients, and Drug and drug conjugation platform. this will be the next $CDTX buyout, $GILD looking yet!

1 · Reply

Johnmtnb2018 Jan. 13 at 4:05 PM

$SLS $CDTX Bidding war like CDTX = $200 +

0 · Reply

Bloenten Jan. 12 at 3:16 PM

$CDTX damn I will miss you, second ever shares I bought and of big sentimental value.. thanks for giving me a nice push into me investing life. Forever grateful!

0 · Reply

Godsgrace2025 Jan. 9 at 11:02 PM

$CDTX God is Good

0 · Reply

Johnmtnb2018 Jan. 8 at 7:42 PM

$CDTX $SLS Yes! Old coot is here at SLS Now!

0 · Reply

Johnmtnb2018 Jan. 8 at 7:40 PM

$CDTX $SLS SLS will part of a big pharmaceutical bidding war in coming days. Mark this post!

2 · Reply

DiamondsPlayz Jan. 7 at 1:56 PM

$CDTX thats actually insane news lets go !

0 · Reply

JohnTrack Jan. 7 at 11:48 AM

$CDTX Sweet cash deal! https://www.rapidticker.com/news/cdtx-merck-to-complete-acquisition-of-e107fb

0 · Reply

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Nov 19, 2025, 1:05 PM EST - 2 months ago

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

MRK

Nov 17, 2025, 8:34 AM EST - 2 months ago

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

MRK

Nov 17, 2025, 8:15 AM EST - 2 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

AVDL

Nov 16, 2025, 6:49 PM EST - 2 months ago

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

MRK

Nov 14, 2025, 6:17 PM EST - 2 months ago

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

IBB MRK XBI XLV

Nov 14, 2025, 4:25 PM EST - 2 months ago

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

Nov 14, 2025, 11:20 AM EST - 2 months ago

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

MRK

Nov 14, 2025, 10:00 AM EST - 2 months ago

NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

MRK NVDA STUB

Nov 14, 2025, 8:30 AM EST - 2 months ago

Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

MRK

Nov 14, 2025, 7:16 AM EST - 2 months ago

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

MRK

Nov 14, 2025, 6:51 AM EST - 2 months ago

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

MRK

Nov 14, 2025, 6:45 AM EST - 2 months ago

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

MRK

Nov 14, 2025, 6:09 AM EST - 2 months ago

Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring

DASH MRK

Nov 13, 2025, 6:53 PM EST - 2 months ago

Merck nearing deal for Cidara, FT reports

MRK

Nov 7, 2025, 2:56 PM EST - 2 months ago

Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:07 PM EST - 2 months ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Cidara Therapeutics to Participate in November Investor Conferences

Oct 23, 2025, 4:05 PM EDT - 3 months ago

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

Oct 23, 2025, 8:00 AM EDT - 3 months ago

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

Oct 21, 2025, 12:52 PM EDT - 3 months ago

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention

Oct 21, 2025, 8:00 AM EDT - 3 months ago

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

Oct 13, 2025, 8:00 AM EDT - 3 months ago

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Oct 10, 2025, 8:00 AM EDT - 3 months ago

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Oct 9, 2025, 8:00 AM EDT - 3 months ago

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Oct 2, 2025, 4:01 PM EDT - 3 months ago

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic

Sep 25, 2025, 4:01 PM EDT - 4 months ago

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

Sep 24, 2025, 7:00 AM EDT - 4 months ago

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza

Sep 17, 2025, 8:00 AM EDT - 4 months ago

Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Sep 9, 2025, 12:41 PM EDT - 4 months ago

Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 8:00 AM EDT - 4 months ago

Cidara Therapeutics to Participate in September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 4 months ago

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Aug 15, 2025, 1:07 PM EDT - 5 months ago

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout

Aug 8, 2025, 6:04 PM EDT - 5 months ago

Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 8:00 AM EDT - 6 months ago

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

Jul 7, 2025, 1:00 PM EDT - 6 months ago

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

Jul 1, 2025, 4:59 PM EDT - 7 months ago

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 5:15 PM EDT - 7 months ago

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 25, 2025, 7:30 AM EDT - 7 months ago

Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy

Jun 24, 2025, 8:00 PM EDT - 7 months ago

Cidara Announces Pricing of Upsized Public Offering of Common Stock

Jun 23, 2025, 4:15 PM EDT - 7 months ago

Cidara Announces Proposed Public Offering of Common Stock

Jun 23, 2025, 11:00 AM EDT - 7 months ago

Why Is Cidara Therapeutics Stock Trading Higher On Monday?

Jun 23, 2025, 7:00 AM EDT - 7 months ago

Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

May 25, 2025, 9:26 PM EDT - 8 months ago

Cidara Therapeutics: All Stars Aligning In Favor Of CD388

May 15, 2025, 8:00 AM EDT - 8 months ago

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

May 13, 2025, 8:00 AM EDT - 8 months ago

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

AlphaOfBiotech Jan. 15 at 5:08 AM

1 · Reply

Pjdevx Jan. 14 at 10:01 PM

$CADL If $CDTX is a 9B acquisition CADL is right up there. Willing to wait.

0 · Reply

Hero07 Jan. 13 at 7:15 PM

$NUVB Dr. Hung knows the Value in stacking ROA1 patients, and Drug and drug conjugation platform. this will be the next $CDTX buyout, $GILD looking yet!

1 · Reply

Johnmtnb2018 Jan. 13 at 4:05 PM

$SLS $CDTX Bidding war like CDTX = $200 +

0 · Reply

Bloenten Jan. 12 at 3:16 PM

$CDTX damn I will miss you, second ever shares I bought and of big sentimental value.. thanks for giving me a nice push into me investing life. Forever grateful!

0 · Reply

Godsgrace2025 Jan. 9 at 11:02 PM

$CDTX God is Good

0 · Reply

Johnmtnb2018 Jan. 8 at 7:42 PM

$CDTX $SLS Yes! Old coot is here at SLS Now!

0 · Reply

Johnmtnb2018 Jan. 8 at 7:40 PM

$CDTX $SLS SLS will part of a big pharmaceutical bidding war in coming days. Mark this post!

2 · Reply

DiamondsPlayz Jan. 7 at 1:56 PM

$CDTX thats actually insane news lets go !

0 · Reply

JohnTrack Jan. 7 at 11:48 AM

$CDTX Sweet cash deal! https://www.rapidticker.com/news/cdtx-merck-to-complete-acquisition-of-e107fb

0 · Reply

StockHawkZero Jan. 7 at 5:59 AM

$AKBA I participated with $CDTX going from R/S and $14 to for 3-5 years to $220 when bought by Merck for 10 billion on the back of no approved drug, but good science platform. The shorts were out in force in the same way there, as they are here. Topic was always "the management is bad". Eff off, you don't know what you are talking about. If you want high level CEO management, who only do and act to please stakeholders, but not always what is right - go invest in big pharma, and not in small/mid biotechs. But you ain't doing it, as the profits are different.

4 · Reply

masonat Jan. 6 at 8:59 PM

$VTYX between this and $CDTX, two very short turnaround times between initiating position and BO recently.

0 · Reply

_nic Jan. 6 at 7:34 PM

$SLS 👀 for the bigger picture. $CDTX had several dips. Watch the price from 3/31/25-4/7/25. dippd from 21 to 16. weeks later - End of june the rocket 🚀 launched. From 20 to 60 and the steadily upwards. Patience

1 · Reply

kareem1988 Jan. 6 at 12:33 PM

Biotechs that hit 52-week highs yesterday: $CDTX: Shares hit $221.24 following a $9.2B acquisition deal by Merck. $DRTS hit a 2-year high yesterday after submitting its first FDA PMA module for Alpha DaRT. With ASCO GI (Jan 8-10) and the JPM Healthcare Conference (Jan 15) ahead, the stock is primed for a breakout toward the $8.00 analyst target. $CRNX: Reached $55.23 on strong launch revenue and positive Phase 2 clinical data. $CRL: Hit $207.14 after a BofA upgrade to Buy with a $225 price target TASH: Touched a 1-year peak following a Goldman Sachs upgrade to an $11 target

0 · Reply

Sellasgps36BAT9 Jan. 5 at 5:13 PM

$CDTX $SLS $SMMT SLS $7.50 up Next 👆

0 · Reply

Peaceouty Jan. 5 at 4:06 PM

$CANF Not to brag, but I’ve held $SMMT $CDTX $BNGO (rip), when they were micro caps, rode them up in the initial spikes. They all had zero institutional interest, quiet social media boards with a few OG believers. They all have something similar in the early stages. Very volatile while the MM lose grip. $CANF is next. $XRP

0 · Reply

Sellasgps36BAT9 Jan. 5 at 3:30 PM

$CDTX $SLS $SMMT SLS PPS breaks $5.00, Next up $7.50 without news. ✌️🙏

0 · Reply

Sellasgps36BAT9 Jan. 5 at 3:22 PM

$CDTX $SLS $SMMT SLS GPS and SLS009 will tackle 40+ cancer types and peek sales of $40 Billion plus by 2030. ✌️🙏❤️‍🩹

0 · Reply

Sellasgps36BAT9 Jan. 5 at 3:09 PM

$CDTX $SLS $SMMT SLS GPS Regal Pivotal Registrational phase 3 study overwhelmingly positive results will show that some patients in GPS ARM living past 5 years. Now that’s head on comparison with BMT(SCT) Bone Marrow transplant = another $2.9 Billion market just in USA. ✌️🙏

0 · Reply

Sellasgps36BAT9 Jan. 5 at 2:44 PM

$CDTX $SLS $SMMT SLS Trading will be halted before deal PR. ✌️🙏

0 · Reply

Sellasgps36BAT9 Jan. 5 at 11:50 AM

$CDTX $SLS $SMMT 06:47 AM EST, 01/05/2026 (MT Newswires) -- The most-talked-about stocks in the Reddit subforum Wallstreetbets were advancing hours before Monday's opening bell. SELLAS Life Sciences Group (SLS) rose by 11%.

0 · Reply

Sellasgps36BAT9 Jan. 5 at 2:56 AM

$SLS $SMMT $CDTX upper channel gap at $21.00+ from 2020/2021 and set a base there before BO PR hits the wires= $120.00+ News will hit in waves now. Market is waking up to the reality of what’s happening here is not one ☝️ but 2 Cancer platforms that will tackle up to 40+ cancer types and dethrone Keytruda is # 1 selling drug on the planet. My Weekend DD points me to first run like SMMT and than Finish with a CDTX type bidding war with 6 or more bidders and ultimate suitor walks away with $200.00+. Right now the move is towards the first base. I expect a PR and Change of control filing along with major option grants for the Sellas Top executives in the coming hours and days ahead. J.P Morgan health conference in SF is matter of days away and Sellas will be in the spotlight that concludes in a bidding war. Big Institutional funds are gobbling up all the loose shares from the weak hands before change of control. 3 year plus GPS Maintenance worth billion upon billions. ✌️🙏❤️‍🩹

3 · Reply

Market Cap	6.95B
Revenue (ttm)	1.28M
Net Income (ttm)	-169.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,267.97%
Debt to Equity Ratio	0.00

Volume	2,691,000
Avg Vol	1,496,326
Day's Range	N/A - N/A
Shares Out	31.44M
Stochastic %K	96%
Beta	1.52
Analysts	Sell
Price Target	$207.30